William Mack & Associates
RPRX icon

William Mack & Associates’s Royalty Pharma RPRX Stock Holding History

William Mack & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.09K Buy
+53
New +$3.13K ﹤0.01% 497

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

William Mack & Associates's RPRX Position: Q3 2026 in Review

William Mack & Associates opened a new position in Royalty Pharma (RPRX) in Q3 2026: 53 shares worth $3.09K. The stake represents ﹤0.01% of the portfolio and ranks #497 among its holdings.

573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • William Mack & Associates held 53 shares of Royalty Pharma worth $3.09K as of Q3 2026.
  • Royalty Pharma was a new William Mack & Associates position in Q3 2026.
  • Royalty Pharma made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #497 holding.
  • 573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.